Galera Therapeutics Inc
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treat… Read more
Galera Therapeutics Inc (GRTX) - Total Liabilities
Latest total liabilities as of December 2024: $153.77 Million USD
Based on the latest financial reports, Galera Therapeutics Inc (GRTX) has total liabilities worth $153.77 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Galera Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Galera Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Galera Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Galera Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LDB Capital Corp.
V:LDB-P
|
Canada | CA$74.34K |
|
Australasian Metals Ltd
AU:A8G
|
Australia | AU$210.16K |
|
Badlands Resources Inc
PINK:BDLNF
|
USA | $3.82 Million |
|
Westar Resources Ltd
AU:WSR
|
Australia | AU$114.20K |
|
NOVARTIS N (NOT.SG)
STU:NOT
|
Germany | €60.08 Billion |
|
OSHKOSH (OK3.SG)
STU:OK3
|
Germany | €5.77 Billion |
|
Jaya Swarasa Agung PT
JK:TAYS
|
Indonesia | Rp308.47 Billion |
|
Nickelsearch Ltd
AU:NIS
|
Australia | AU$2.63 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Galera Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 15.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galera Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galera Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Galera Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $153.77 Million | -2.26% |
| 2023-12-31 | $157.33 Million | +2.68% |
| 2022-12-31 | $153.22 Million | +8.42% |
| 2021-12-31 | $141.31 Million | +81.22% |
| 2020-12-31 | $77.98 Million | +45.03% |
| 2019-12-31 | $53.77 Million | -72.12% |
| 2018-12-31 | $192.88 Million | +103.08% |
| 2017-12-31 | $94.98 Million | -- |